Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hee Seung | - |
dc.contributor.author | Kim, Mi-Kyung | - |
dc.contributor.author | Kim, Hak Jae | - |
dc.contributor.author | Han, Seung-Su | - |
dc.contributor.author | Kim, Jae Weon | - |
dc.date.available | 2019-05-29T07:34:26Z | - |
dc.date.issued | 2012-06 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.issn | 2005-9256 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/20310 | - |
dc.description.abstract | Purpose This study investigated the efficacy and toxicity associated with consolidation chemotherapy using paclitaxel and carboplatin after concurrent chemoradiation (CCR) in cervical cancer patients. Materials and Methods From a total of 37 patients, 19 with International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IIA cervical cancer (group 1) underwent surgery followed by consolidation chemotherapy after CCR, and 18 with stage IIB-IVA disease (group 2) received consolidation chemotherapy after primary CCR. Three cycles of chemotherapy using paclitaxel (135 mg/m(2)) and carboplatin (AUC 5.0) were administered every 3 weeks for CCR therapy, and three cycles of consolidation chemotherapy using paclitaxel (175 mg/m(2)) and carboplatin (AUC 5.0) were used every 3 weeks after CCR. Results The complete and partial response rates were 77.8% and 22.2% in group 2. Moreover, the 3-year progression-free and overall survival rates were 62.7% and 90.9% in group 1, and 51.9% and 60% in group 2, respectively. The most common grade 3 or 4 hematologic toxicities observed were leukopenia (group 1, 10.5%; group 2, 13.0%) and neutropenia (group 1, 7.0%; group 2, 14.8%), and grade 3 or 4 diarrhea (group 1, 1.8%) and febrile illness (group 2, 1.9%) were the most frequently observed non-hematologic toxicities. When we compared these results with previous reports, consolidation chemotherapy after CCR using paclitaxel and carboplatin revealed a relatively lower complete response rate (77.8% vs. 87-100%, respectively) and shorter progression-free survival (51.9-62.7% vs. 81-86%, respectively) and overall survival (60-90.9% vs. 81-95%, respectively) in spite of similar toxicity findings. Conclusion Due to low efficacy results, consolidation chemotherapy using paclitaxel and carboplatin after CCR is not a feasible treatment regimen for high-risk early-stage or locally advanced cervical cancer. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN CANCER ASSOCIATION | - |
dc.title | Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer | - |
dc.type | Article | - |
dc.identifier.doi | 10.4143/crt.2012.44.2.97 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, v.44, no.2, pp 97 - 103 | - |
dc.identifier.kciid | ART001671243 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000309999800004 | - |
dc.identifier.scopusid | 2-s2.0-84866893998 | - |
dc.citation.endPage | 103 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 97 | - |
dc.citation.title | CANCER RESEARCH AND TREATMENT | - |
dc.citation.volume | 44 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Consolidation chemotherapy | - |
dc.subject.keywordAuthor | Chemoradiotherapy | - |
dc.subject.keywordAuthor | Paclitaxel | - |
dc.subject.keywordAuthor | Carboplatin | - |
dc.subject.keywordAuthor | Uterine cervical neoplasms | - |
dc.subject.keywordPlus | SQUAMOUS-CELL CARCINOMA | - |
dc.subject.keywordPlus | UTERINE CERVIX | - |
dc.subject.keywordPlus | GYNECOLOGIC CANCER | - |
dc.subject.keywordPlus | RATE BRACHYTHERAPY | - |
dc.subject.keywordPlus | OVARIAN-CANCER | - |
dc.subject.keywordPlus | ONCOLOGY-GROUP | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | RADIOTHERAPY | - |
dc.subject.keywordPlus | TRIAL | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.